November 27, 2015
A recent Cochrane Review indicated methylphenidate may improve teacher-reported attention-deficit/hyperactivity disorder symptoms, teacher-reported general behavior and parent-reported quality of life among youth with the disorder, however, evidence was low-quality and therefore could not confirm findings.
To assess benefits and harms of methylphenidate for children and adolescents with attention-deficit/hyperactivity disorder (ADHD), Ole Jakob Storebø, PhD, of University of Southern Denmark, Odense, Denmark, and colleagues analyzed 185 randomized trials that compared methylphenidate with placebo or no intervention among youth with ADHD. Analysis included 38 parallel-group trials with 5,111 randomized participants and 147 cross-over trials with 7,134 randomized participants. Study participants had a mean age of 9.7 years.